Relugolix is an oral medication, often used in combination with estradiol and norethindrone acetate to form the fixed-dose combination product relugolix. It is mainly indicated for the treatment of heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis.

What Are the Indications of Relugolix?

Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Relugolix is indicated for the treatment of heavy menstrual bleeding caused by uterine fibroids (leiomyomas) in premenopausal women.

Clinical trials have shown that the use of this medication can significantly reduce menstrual blood loss and improve patients' quality of life.

Studies have demonstrated that over 70% of patients experienced a significant reduction in menstrual blood loss after 24 weeks of treatment, and some patients even developed amenorrhea.

Management of Pain Associated with Endometriosis

This medication is also indicated for the treatment of moderate to severe pain caused by endometriosis in premenopausal women.

Clinical trials have confirmed that relugolix can effectively relieve dysmenorrhea and non-menstrual pelvic pain, improve patients' ability to perform daily activities, and reduce dependence on analgesic drugs.

Usage Limitations

It should be noted that the duration of relugolix use should be limited to 24 months or less.

Long-term use may lead to decreased bone mineral density, and this bone loss may be irreversible.

During the treatment period, regular bone mineral density monitoring is required, and the risks and benefits of continuing treatment should be evaluated based on the doctor's advice.

Dosage Form and Appearance of Relugolix

Drug Ingredients

Each relugolix tablet is a fixed-dose combination preparation containing the following three active ingredients.

Relugolix 40mg.

Estradiol 1mg.

Norethindrone acetate 0.5mg.

Dosage Form and Appearance

Relugolix is an oral film-coated tablet, appearing light yellow to yellow and round in shape.

One side of the tablet is engraved with "MVT" and the other side with "415" for easy identification.

Excipient Ingredients

In addition to the active ingredients, the tablets also contain the following excipients: lactose monohydrate, mannitol, hypromellose, hydroxypropyl cellulose, magnesium stearate, sodium starch glycolate, titanium dioxide, triacetin, and yellow iron oxide.

Storage Method of Relugolix

Storage Conditions

Relugolix should be stored at a temperature between 15°C and 30°C (59°F and 86°F), away from excessive heat, moisture, and direct sunlight.

Drug Disposal

Unused medications should be disposed of through drug recycling programs.

Precautions

Keep the medication out of the reach of children to prevent accidental ingestion.

Regularly check the expiration date of the medication and do not use expired products.